文章摘要
范晓萍,于子溢,楼龙泉,肇 毅.c⁃Src在乳腺癌抗雌激素受体α治疗过程中的表达变化及其耐药机制的研究[J].南京医科大学学报,2019,(7):966~970
c⁃Src在乳腺癌抗雌激素受体α治疗过程中的表达变化及其耐药机制的研究
Study on the alteration of c⁃Src during anti⁃estrogen receptor α therapy and mechanisms of resistance mediated by c⁃Src in breast cancer cells
投稿时间:2018-09-26  
DOI:10.7655/NYDXBNS20190704
中文关键词: 原癌基因c⁃Src  乳腺癌  雌激素受体  表皮生长因子受体  耐药
英文关键词: oncogene c⁃Src  breast cancer  estrogen receptor  epidermal growth factor receptor  resistance
基金项目:江苏省人力资源和社会保障厅“六大人才高峰”资助项目(2013?WSW?026)
作者单位
范晓萍 南京医科大学第二附属医院超声医学科江苏 南京 210011 
于子溢 南京医科大学第一附属医院乳腺外科江苏 南京 210029 
楼龙泉 南京医科大学第一附属医院乳腺外科江苏 南京 210029 
肇 毅 南京医科大学第一附属医院乳腺外科江苏 南京 210029 
摘要点击次数: 69
全文下载次数: 107
中文摘要:
      目的:探讨原癌基因c?Src在乳腺癌抗雌激素受体α(estrogen receptor,ERα)治疗过程中的变化及其耐药机制。方法:用雌激素受体阻滞剂三苯氧胺(tamoxifen,TAM)长期处理ERα阳性的MCF?7细胞建立TAM耐药细胞(TAM?R)。用免疫印迹实验检测c?Src、ERα、表皮生长因子受体(epidermal growth factor receptor,EGFR)在耐药细胞上的表达,用免疫沉淀法检测这些分子间的相互作用,并用c?Src抑制剂PP2阻断其磷酸化,观察其对耐药的逆转作用。结果:与原生的MCF?7细胞相比,c?Src、ERα、EGFR在TAM?R上的表达量没有改变,但是,c?Src磷酸化水平在耐药细胞上表达明显增高。并且在耐药细胞上,ERα与EGFR之间的相互结合明显增高,PP2可以明显阻断两分子间的相互作用。更重要的是,经PP2处理后耐药细胞的生长可再次被TAM抑制,即PP2可以逆转耐药细胞的耐药性。结论:c?Src是介导ERα与EGFR之间相互作用的关键分子,阻断这种相互作用可以重新获得对TAM治疗的敏感性,提示c?Src抑制剂可以和TAM交替使用来提高乳腺癌的治疗效果。
英文摘要:
      Objective:To investigate the function of oncogene c?Src in the process of anti?estrogen receptor α therapy and how it mediates the resistance in estrogen receptor(ER)?positive breast cancer cells. Methods:Wild?type MCF?7 cells were long?term treated with tamoxifen(TAM) and established tamoxifen resistant cells(TAM?R). The expression of c?Src,ERα,and epithelial growth factor receptor(EGFR) was detected by immunoblotting. The interactions between ERα and EGFR were measured by immunoprecipitation. The c?Src inhibitor PP2 was used to block the tyrosine kinase activity of c?Src. Results:Compared with wild?type MCF?7 cells,expression levels of ERα,EGFR,and c?Src were not altered in TAM?R cells. However,the phosphorylation of c?Src was increased in TAM?R cells. Further examination demonstrated that interaction between ERα and EGFR was increased in TAM?R cells. Blocking c?Src phosphorylation by PP2 dissociated the interaction between ERα and EGFR in TAM?R cells. Importantly, TAM could onceagain remarkably inhibit cell growth of TAM?R cells after treated by PP2. Thus,the c?Src inhibitor could reverse TAM?R cells to TAM?sensitive cells. Conclusion:Our results suggested that c?Src is a critical molecule to mediate tamoxifen resistance in breast cancer cells through increasing the interaction between ERα and EGFR. Blocking interaction between ERα and EGFR by PP2 can recover the sensitivity to TAM in resistant cells. All of these findings demonstrated that the c?Src inhibitor can be alternatively used with ERα target therapy to treat ER?positive breast cancer thereby improving the therapeutic effects on breast cancer patients.
查看全文   查看/发表评论  下载PDF阅读器
关闭